Table 4 Uptake of risk-based guideline recommendations
Guideline Recommendation | Familial risk recommendation (% of total population, 95% CI) | Pre-intervention Uptake of risk-based guidelines | Post-intervention Uptake of risk-based guidelines | ||
|---|---|---|---|---|---|
Provider uptake (%, 95% CI)a | Patient uptake (%, 95% CI)b | Provider uptake (%, 95% CI)a | Patient uptake (%, 95% CI)b | ||
Any familial recommendation | 278 (15.2, 13.6—16.9) | 69 (22.6) | 48 (69.6) | 83 (27.2) | 69 (81.2) |
 • Breast MRI | 54 (3.0, 2.2—3.9) | 3 (5.5, 1.4 -16.3) | 3 (100, 31.0—100) | 6 (11.1, 4.6 – 23.3) | 4 (66.6, 24.1 – 94.0) |
 • Chemoprevention | 106 (5.8, 4.8—7.0) | 0 (0, 0 – 4.4) | 0 | 0 (0, 0 – 4.4) | 0 |
 • Early or EMF CRC Screening (for patients < 50) | 67 (3.7, 2.9—4.7) | 19 (28.4, 18.3 – 40.9) | 13 (68.4, 43.5 – 86.4) | 24 (35.8, 24.7 – 48.5) | 19 (79.2, 57.3 – 92.0) |
 • EMF (for patients >  = 50) | 78 (4.3, 3.4—5.3) | 47 (60.3, 48.5 – 71.0) | 32 (68.1, 52.7 – 80.5) | 53 (67.9, 56.3 – 77.8) | 46 (86.8, 74.0 – 94.1) |
Monogenic recommendation | 543 (29.7, 27.6—31.9) | n/ac | n/ac | 51 (9.4, 7.1 – 12.2) | 34 (66.7, 52.0 – 78.9) |